JP3679710B2 - 外科手術上の癒着を阻止するためのデキストリンを含有する組成物 - Google Patents
外科手術上の癒着を阻止するためのデキストリンを含有する組成物 Download PDFInfo
- Publication number
- JP3679710B2 JP3679710B2 JP2000548018A JP2000548018A JP3679710B2 JP 3679710 B2 JP3679710 B2 JP 3679710B2 JP 2000548018 A JP2000548018 A JP 2000548018A JP 2000548018 A JP2000548018 A JP 2000548018A JP 3679710 B2 JP3679710 B2 JP 3679710B2
- Authority
- JP
- Japan
- Prior art keywords
- dextrin
- composition
- composition according
- body cavity
- adhesions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 229920001353 Dextrin Polymers 0.000 title claims abstract description 48
- 239000004375 Dextrin Substances 0.000 title claims abstract description 48
- 235000019425 dextrin Nutrition 0.000 title claims abstract description 48
- 208000031737 Tissue Adhesions Diseases 0.000 title description 7
- 230000002401 inhibitory effect Effects 0.000 title description 4
- 150000004676 glycans Chemical class 0.000 claims abstract description 8
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 7
- 239000005017 polysaccharide Substances 0.000 claims abstract description 7
- 206010060932 Postoperative adhesion Diseases 0.000 claims abstract description 3
- 229920000642 polymer Polymers 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 11
- 238000001356 surgical procedure Methods 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 9
- 239000013011 aqueous formulation Substances 0.000 claims description 9
- 238000006116 polymerization reaction Methods 0.000 claims description 6
- 102000009123 Fibrin Human genes 0.000 claims description 5
- 108010073385 Fibrin Proteins 0.000 claims description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 5
- 229950003499 fibrin Drugs 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000008929 regeneration Effects 0.000 claims description 2
- 238000011069 regeneration method Methods 0.000 claims description 2
- 230000008439 repair process Effects 0.000 claims description 2
- 238000002386 leaching Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 5
- 239000007864 aqueous solution Substances 0.000 abstract description 4
- 239000007900 aqueous suspension Substances 0.000 abstract 1
- 239000000499 gel Substances 0.000 abstract 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 11
- 229940068196 placebo Drugs 0.000 description 9
- 239000000902 placebo Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 210000004303 peritoneum Anatomy 0.000 description 7
- 239000012530 fluid Substances 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000009545 invasion Effects 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 238000011887 Necropsy Methods 0.000 description 3
- 229920006318 anionic polymer Polymers 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229960002086 dextran Drugs 0.000 description 3
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 3
- 229960001123 epoprostenol Drugs 0.000 description 3
- 229940014041 hyaluronate Drugs 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000002357 laparoscopic surgery Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 2
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920000310 Alpha glucan Polymers 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 229920004937 Dexon® Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000009120 Elymus fibrosus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010058674 Pelvic Infection Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 239000002357 osmotic agent Substances 0.000 description 1
- 229940043138 pentosan polysulfate Drugs 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- -1 wheat Natural products 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/041—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Surgery (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9810127.2 | 1998-05-13 | ||
| GBGB9810127.2A GB9810127D0 (en) | 1998-05-13 | 1998-05-13 | Prevention of surgical adhesions |
| US27271399A | 1999-03-19 | 1999-03-19 | |
| US09/272,713 | 1999-03-19 | ||
| PCT/GB1999/001306 WO1999058168A1 (en) | 1998-05-13 | 1999-05-13 | Dextrin-containing composition for preventing surgical adhesions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004273531A Division JP4276601B2 (ja) | 1998-05-13 | 2004-09-21 | 外科手術上の癒着を阻止するためのデキストリンを含有する組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003528026A JP2003528026A (ja) | 2003-09-24 |
| JP3679710B2 true JP3679710B2 (ja) | 2005-08-03 |
Family
ID=26313653
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000548018A Expired - Lifetime JP3679710B2 (ja) | 1998-05-13 | 1999-05-13 | 外科手術上の癒着を阻止するためのデキストリンを含有する組成物 |
| JP2004273531A Expired - Lifetime JP4276601B2 (ja) | 1998-05-13 | 2004-09-21 | 外科手術上の癒着を阻止するためのデキストリンを含有する組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004273531A Expired - Lifetime JP4276601B2 (ja) | 1998-05-13 | 2004-09-21 | 外科手術上の癒着を阻止するためのデキストリンを含有する組成物 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1085920B1 (enExample) |
| JP (2) | JP3679710B2 (enExample) |
| CN (1) | CN1181894C (enExample) |
| AT (1) | ATE211002T1 (enExample) |
| AU (1) | AU740832B2 (enExample) |
| BR (1) | BR9911769B8 (enExample) |
| CA (1) | CA2331672C (enExample) |
| DE (1) | DE69900648T2 (enExample) |
| DK (1) | DK1085920T3 (enExample) |
| ES (1) | ES2165735T3 (enExample) |
| IL (2) | IL139283A0 (enExample) |
| NO (1) | NO312709B1 (enExample) |
| NZ (2) | NZ507832A (enExample) |
| PL (1) | PL194109B1 (enExample) |
| PT (1) | PT1085920E (enExample) |
| WO (1) | WO1999058168A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2363713A (en) * | 2000-06-21 | 2002-01-09 | Ml Lab Plc | Dextrin compositions |
| CA2392666C (en) * | 2000-01-21 | 2011-12-13 | Ml Laboratories Plc | Dextrin containing compositions for prevention of adhesions |
| GB0115505D0 (en) * | 2001-06-25 | 2001-08-15 | Britannia Pharmaceuticals Ltd | Prevention of surgical adhesions |
| US8252333B2 (en) * | 2006-01-26 | 2012-08-28 | Jorge Cueto-Garcia | Biodegradable, non-toxic biological adhesive for use in abdominal surgery |
| US8455001B2 (en) | 2007-02-06 | 2013-06-04 | Teijin Limited | Cellulose derivative and method for production thereof |
| DE102008005172A1 (de) * | 2008-01-19 | 2009-07-23 | Mike Ehrlich | Pharmazeutische Zusammensetzung zur Verhinderung von post-operativen Adhäsionen |
| EP2676682A1 (en) * | 2011-02-08 | 2013-12-25 | Jorge Cueto García | Thixotropic biological adhesive for use in internal body cavities |
| US20220265896A1 (en) * | 2019-08-01 | 2022-08-25 | Km Biologics Co., Ltd. | Tissue fibrosis inhibitor in which biocompatible polymer is used |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0207676B1 (en) * | 1985-06-22 | 1994-06-01 | M L Laboratories Plc | Polymers for use in continuous peritoneal dialysis |
| SE457933B (sv) * | 1987-07-06 | 1989-02-13 | Larsson Kare | Farmaceutisk komposition innefattande en vattendispergerad blandning av lipider, monoglycerider och fosfatidylkolin samt dess anvaendning foer framstaellning av en gastronintestinalt verksam kompostion |
| SE8900586L (sv) * | 1989-02-21 | 1990-08-22 | Pharmacia Ab | Komposition och foerfarande foer att foerhindra adhesion mellan kroppsvaevnader |
| US5093319A (en) * | 1989-10-31 | 1992-03-03 | Pfizer Hospital Products Group, Inc. | Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions |
| EP0426368B1 (en) * | 1989-10-31 | 1995-01-04 | Howmedica Inc. | Compositions containing derivatives of chitin for preventing adhesion |
| US5318780A (en) * | 1991-10-30 | 1994-06-07 | Mediventures Inc. | Medical uses of in situ formed gels |
| US5614515A (en) * | 1994-11-17 | 1997-03-25 | University Of Southern California | Lazaroid-based compositions and method for preventing adhesion formation using the same |
| US5807833A (en) * | 1995-06-07 | 1998-09-15 | University Of Southern California | Hydroxyethyl starch and use thereof as an absorbable mechanical barrier and intracavity carrier device |
| CA2223590A1 (en) * | 1995-06-07 | 1996-12-19 | The University Of Southern California | Method for reducing or preventing post-surgical adhesion formation using 5-lipoxygenase inhibitors |
| JP3925955B2 (ja) * | 1996-04-26 | 2007-06-06 | 株式会社クラレ | 癒着防止材 |
| IN192791B (enExample) * | 1996-06-28 | 2004-05-22 | Johnson & Johnson Medical |
-
1999
- 1999-05-13 NZ NZ507832A patent/NZ507832A/xx not_active IP Right Cessation
- 1999-05-13 CN CNB998060836A patent/CN1181894C/zh not_active Expired - Lifetime
- 1999-05-13 PL PL99344536A patent/PL194109B1/pl unknown
- 1999-05-13 DE DE69900648T patent/DE69900648T2/de not_active Expired - Lifetime
- 1999-05-13 NZ NZ523994A patent/NZ523994A/en not_active IP Right Cessation
- 1999-05-13 EP EP99920952A patent/EP1085920B1/en not_active Expired - Lifetime
- 1999-05-13 CA CA002331672A patent/CA2331672C/en not_active Expired - Lifetime
- 1999-05-13 PT PT99920952T patent/PT1085920E/pt unknown
- 1999-05-13 DK DK99920952T patent/DK1085920T3/da active
- 1999-05-13 WO PCT/GB1999/001306 patent/WO1999058168A1/en not_active Ceased
- 1999-05-13 ES ES99920952T patent/ES2165735T3/es not_active Expired - Lifetime
- 1999-05-13 IL IL13928399A patent/IL139283A0/xx active IP Right Grant
- 1999-05-13 AU AU38336/99A patent/AU740832B2/en not_active Expired
- 1999-05-13 JP JP2000548018A patent/JP3679710B2/ja not_active Expired - Lifetime
- 1999-05-13 AT AT99920952T patent/ATE211002T1/de active
- 1999-05-13 BR BRPI9911769A patent/BR9911769B8/pt not_active IP Right Cessation
-
2000
- 2000-10-26 IL IL139283A patent/IL139283A/en not_active IP Right Cessation
- 2000-11-01 NO NO20005492A patent/NO312709B1/no not_active IP Right Cessation
-
2004
- 2004-09-21 JP JP2004273531A patent/JP4276601B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| BR9911769B8 (pt) | 2021-06-22 |
| JP4276601B2 (ja) | 2009-06-10 |
| CA2331672C (en) | 2007-02-06 |
| NO20005492L (no) | 2001-01-12 |
| BR9911769A (pt) | 2001-02-06 |
| ES2165735T3 (es) | 2002-03-16 |
| DE69900648D1 (de) | 2002-01-31 |
| CN1181894C (zh) | 2004-12-29 |
| JP2005047929A (ja) | 2005-02-24 |
| EP1085920B1 (en) | 2001-12-19 |
| NO20005492D0 (no) | 2000-11-01 |
| AU740832B2 (en) | 2001-11-15 |
| EP1085920A1 (en) | 2001-03-28 |
| CA2331672A1 (en) | 1999-11-18 |
| NZ523994A (en) | 2004-11-26 |
| NZ507832A (en) | 2003-03-28 |
| PL344536A1 (en) | 2001-11-05 |
| JP2003528026A (ja) | 2003-09-24 |
| HK1034680A1 (en) | 2001-11-02 |
| BR9911769B1 (pt) | 2014-10-07 |
| PL194109B1 (pl) | 2007-04-30 |
| CN1300226A (zh) | 2001-06-20 |
| NO312709B1 (no) | 2002-06-24 |
| ATE211002T1 (de) | 2002-01-15 |
| IL139283A (en) | 2007-02-11 |
| AU3833699A (en) | 1999-11-29 |
| DE69900648T2 (de) | 2002-07-04 |
| PT1085920E (pt) | 2002-06-28 |
| IL139283A0 (en) | 2001-11-25 |
| DK1085920T3 (da) | 2002-04-15 |
| WO1999058168A1 (en) | 1999-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5489999B2 (ja) | 外科用ハイドロゲル | |
| JP5425216B2 (ja) | 癒着防止用組成物 | |
| JP3679710B2 (ja) | 外科手術上の癒着を阻止するためのデキストリンを含有する組成物 | |
| US8642574B2 (en) | Surgical compositions for reducing the incidence of adhesions | |
| US20230040901A1 (en) | Pharmaceutical composition for inhibiting postoperative adhesions | |
| JP4999247B2 (ja) | 癒着を防止するためのデキストリン含有組成物 | |
| JP2002536323A (ja) | 膿瘍形成の予防 | |
| MXPA00011106A (en) | Dextrin-containing composition for preventing surgical adhesions | |
| HK1034680B (en) | Dextrin-containing composition for preventing surgical adhesions | |
| CN119454748A (zh) | 一种治疗骨性关节炎的复合交联结构及其用途 | |
| GB2363713A (en) | Dextrin compositions | |
| HK1161128B (zh) | 用於防止粘连的组合物 | |
| JPWO1998029125A1 (ja) | 膀胱障害治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040521 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040921 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040921 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20050210 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050419 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050513 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
| R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080520 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090520 Year of fee payment: 4 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090520 Year of fee payment: 4 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100520 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110520 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110520 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120520 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120520 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130520 Year of fee payment: 8 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |